The smaller the sample size usually the more difficult it is to prove something is statistically significant. Making Anavex p values even more impressive. If we are going based on the drugs already available Anavex is much safer(no one has died or had any serious adverse events) and slows your decline. Why wouldn’t you allow it on the market while running a confirmation trial for people who have no other available options?!
The safety record for Anavex Blarcamesine is unparalleled in Alzheimer's drugs. The oral administration is superior and it doesn't require extensive, expensive follow ups to try and protect patients.
Market Data 
Markets 
AI
